Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Lot-to-lot consistency study of the fully liquid pentavalent DTwP-HepB-Hib vaccine Quinvaxem (®) demonstrating clinical equivalence, suitability of the vaccine as a booster and concomitant administration with measles vaccine.

Aspinall S, Traynor D, Bedford P, Hartmann K.

Hum Vaccin Immunother. 2012 Aug;8(8):1109-18. doi: 10.4161/hv.21095. Erratum in: Hum Vaccin Immunother. 2013 Apr;9(4):937.

2.

A phase III single arm, multicenter, open-label study to assess the immunogenicity and tolerability of a pentavalent DTwP-HepB-Hib vaccine in indian infants.

Eregowda A, Lalwani S, Chatterjee S, Vakil H, Ahmed K, Costantini M, Lattanzi M.

Hum Vaccin Immunother. 2013 Sep;9(9):1903-9. doi: 10.4161/hv.25166.

3.

Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.

Halperin SA, Tapiéro B, Dionne M, Meekison W, Diaz-Mitoma F, Zickler P, Rubin E, Embree J, Bhuyan P, Lee A, Li M, Tomovici A.

Pediatr Infect Dis J. 2014 Jan;33(1):73-80. doi: 10.1097/01.inf.0000437806.76221.20.

PMID:
24346596
4.

Immunogenicity and safety of an indigenously manufactured reconstituted pentavalent (DTwP-HBV+Hib) vaccine in comparison with a foreign competitor following primary and booster immunization in Indian children.

Sharma HJ, Yadav S, Lalwani SK, Kapre SV, Jadhav SS, Chakravarty A, Parekh SS, Palkar S, Bhardwaj SH, Namjoshi GS, Verma V.

Hum Vaccin. 2011 Apr;7(4):451-7.

PMID:
21403463
5.

Antibody persistence of two pentavalent DTwP-HB-Hib vaccines to the age of 15-18 months, and response to the booster dose of quadrivalent DTwP-Hib vaccine.

Sharma H, Yadav S, Lalwani S, Kapre S, Jadhav S, Parekh S, Palkar S, Ravetkar S, Bahl S, Kumar R, Shewale S.

Vaccine. 2013 Jan 7;31(3):444-7. doi: 10.1016/j.vaccine.2012.11.038.

PMID:
23196204
6.

Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants.

Madhi SA, Koen A, Cutland C, Groome M, Santos-Lima E.

Pediatr Infect Dis J. 2013 Aug;32(8):889-97. doi: 10.1097/INF.0b013e318292f7b1.

PMID:
23538523
7.

Immunogenicity and reactogenicity of a combined fully liquid DTPw-HepB-Hib pentavalent vaccine in healthy infants: no clinically relevant impact of a birth dose of hepatitis B vaccine.

Gentile A, Umido V, Czerniuk P, Nacul J, Seigelchifer M, Hilbert AK, Yela U, Herzog C, Aeberhard U, Spyr C.

Int J Infect Dis. 2011 Jan;15(1):e24-9. doi: 10.1016/j.ijid.2010.09.004.

8.

Interchangeability of Quinvaxem during primary vaccination schedules: results from a phase IV, single-blind, randomized, controlled, single-center, non-inferiority study.

Capeding MR, Jica C, Macura-Biegun A, Rauscher M, Alberto E.

Vaccine. 2014 Feb 7;32(7):888-94. doi: 10.1016/j.vaccine.2013.10.059.

9.

Development and introduction of a ready-to-use pediatric pentavalent vaccine to meet and sustain the needs of developing countries--Quinvaxem®: the first 5 years.

Schmid DA, Macura-Biegun A, Rauscher M.

Vaccine. 2012 Sep 28;30(44):6241-8. doi: 10.1016/j.vaccine.2012.07.088. Review.

PMID:
22889824
10.

Immunogenicity and safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad ®) administered concomitantly with a booster dose of a hexavalent vaccine in 12-23-month-old infants.

Deichmann KA, Ferrera G, Tran C, Thomas S, Eymin C, Baudin M.

Vaccine. 2015 May 11;33(20):2379-86. doi: 10.1016/j.vaccine.2015.02.070.

PMID:
25765966
11.

A fully liquid DTPw-HepB-Hib combination vaccine for booster vaccination of toddlers in El Salvador.

Suárez E, Asturias EJ, Hilbert AK, Herzog C, Aeberhard U, Spyr C.

Rev Panam Salud Publica. 2010 Feb;27(2):117-24.

12.
13.

Safety and immunogenicity of a new fully liquid DTPw-HepB-Hib combination vaccine in infants.

Kanra G, Kara A, Demiralp O, Contorni M, Hilbert AK, Spyr C, Viviani S.

Hum Vaccin. 2006 Jul-Aug;2(4):155-60.

PMID:
17012890
14.

Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants.

Olivier C, Belohradsky BH, Stojanov S, Bonnet E, Petersen G, Liese JG.

Vaccine. 2008 Jun 13;26(25):3142-52. doi: 10.1016/j.vaccine.2007.11.096.

PMID:
18502545
15.
16.

Safety and immunogenicity of a hexavalent vaccine administered at 2, 4 and 6 months of age with or without a heptavalent pneumococcal conjugate vaccine: a randomized, open-label study.

Tapiéro B, Halperin SA, Dionne M, Meekison W, Diaz-Mitoma F, Zickler P, Rubin E, Embree J, Bhuyan P, Lee AW, Li M, Tomovici A.

Pediatr Infect Dis J. 2013 Jan;32(1):54-61. doi: 10.1097/INF.0b013e3182717edf.

PMID:
23241989
18.
20.

Primary and booster vaccination with DTPw-HB/Hib pentavalent vaccine in Costa Rican children who had received a birth dose of hepatitis B vaccine.

Faingezicht I, Avila-Aguerro ML, Cervantes Y, Fourneau M, Clemens SA.

Rev Panam Salud Publica. 2002 Oct;12(4):247-57.

PMID:
12431356
Items per page

Supplemental Content

Support Center